Anxiolytic therapy

2:

• The method of claim 1, where the anxiolytic agent comprises at least one of a small molecule, nucleic, peptide, protein, or antibody that inhibits asprosin binding to PTPRD or PTPRD signaling or activity.

3:

• The method of claim 1, wherein the anxiolytic agent comprises an antibody or antigen binding fragment that specifically binds to a peptide having an amino acid sequence of KKKELNQLEDRYDKDYLSGELGDNLKMK (SEQ ID NO:
• 1), wherein the antibody or antigen binding fragment thereof includes a heavy chain variable region and/or light variable region that includes three heavy chain CDRs and/or three light chain CDR of an antibody produced by hybridoma cell line deposited with the American Type Culture Collection under accession number ATCC PTA-123085.

(canceled)

5:

• The method of claim 3, wherein the antibody or antigen binding fragment thereof is a humanized antibody or antigen binding fragment thereof.

6:

• The method of claim 3, wherein the antibody or antigen binding fragment thereof is monospecific or bispecific antibody or antigen binding fragment thereof.

7:

• The method of claim 1, wherein the anxiolytic agent is an anxiolytic peptide that includes an amino acid sequence substantially identical to an extracellular portion of the amino acid sequence of PTPRD that binds to asprosin.

8:

• The method of claim 7, wherein the anxiolytic peptide has an amino acid sequence at least about 90% identical to at least 1000 consecutive amino acids of SEQ ID NO:
• 2.

9:

• The method of claim 7, wherein the anxiolytic peptide has an amino acid sequence at least about 90% identical to SEQ ID NO:
• 2.

10:

• The method of claim 7, wherein the anxiolytic peptide has an amino acid sequence at least about 90% identical to at least about 200 consecutive amino acids of SEQ ID NO:
• 3.

11:

• The method of claim 8, wherein the anxiolytic peptide has a binding affinity KD to asprosin less than about 1 μM.

12:

• The method of claim 8, wherein the anxiolytic peptide is linked to at least one heterologous polypeptide.

13:

• The method of claim 12, wherein the at least one heterologous polypeptide comprises an antibody or antigen binding fragment thereof, a glucagon-like peptide-1 receptor (GLP-1R) agonist, a Fc portion of an immunoglobulin, an albumin peptide, an albumin binding domain (ABD), a peptide linker, a signal peptide, or a combination thereof.

14:

• The method of claim 1, wherein the anxiety disorder is one or more generalized anxiety disorder, phobia, social anxiety disorder, social phobia, panic disorder, panic attack, post-traumatic stress disorder, separation anxiety disorder, selective mutism, agoraphobia, or an anxiety disorder induced by a substance/medication or due to a medical condition.

15:

• The method of claim 1, wherein the subject has anxiety disorder as well as one or more of attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorder, Tourette's syndrome, phobia, obsessive compulsive disorder (OCD), difficulty controlling anger, disruptive behaviors, dermatillomania, a developmental disorder, a mood disorder, a movement disorder, or depression.

16-19. (canceled)

20:

• An anxiolytic agent comprising an anxiolytic peptide that includes an amino acid sequence substantially identical to an extracellular portion of the amino acid sequence of PTPRD that binds to asprosin, wherein the anxiolyitic peptide is linked to at least one heterologous polypeptide.

21:

• The anxiolytic agent of claim 20, wherein the anxiolytic peptide has an amino acid sequence at least about 90% identical to at least 1000 consecutive amino acids of SEQ ID NO:
• 2.

22:

• The anxiolytic agent of claim 21, wherein the anxiolytic peptide has an amino acid sequence at least about 90% identical to SEQ ID NO:
• 2.

23:

• The anxiolytic agent of claim 22, wherein the anxiolytic peptide has an amino acid sequence at least about 90 identical to at least about 200 consecutive amino acids of SEQ ID NO:
• 3.

24:

• The anxiolytic agent of claim 20, wherein the anxiolytic peptide has a binding affinity KD to asprosin less than about 1 μM.

(canceled)

26:

• The anxiolytic agent of claim 20, wherein the at least one heterologous polypeptide comprises an antibody or antigen binding fragment thereof, a glucagon-like peptide-1 receptor (GLP-1R) agonist, a Fc portion of an immunoglobulin, an albumin peptide, an albumin binding domain (ABD), a peptide linker, a signal peptide, or a combination thereof.